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specimens to investigate whether it could allow 
discrimination of sensitive and resistant tumours of the same 
type. In addition we aimed to further explore the robustness 
of the method via investigating the potential impact of the 
tumour sampling on the reproducibility of the results. 
 
Material and Methods: Tumour biopsies from prostate cancer 
patients undergone radical prostatectomy were cultivated in 
media for 24 h before irradiation (IR) with single doses and 
fixed 24 h post IR. The microenvironmental parameters were 
determined by addition of BrdU (perfusion) and Pimonidazole 
(hypoxia) to media prior to IR. Histological sections of 
previously paraffin-embedded material were stained for 
γH2AX and the foci were evaluated in viable, well 
oxygenated tumour areas. To investigate the heterogeneity 
of radiation response among the different patients, biopsies 
were irradiated with graded single doses (0, 2, 4, 6, 8 Gy) 
while to determine the intratumoural sampling variability, 
biopsies from different tumour locations were irradiated with 
single dose of 4 Gy. 
 
Results: In all the 15 patients currently analyzed we 
observed a linear dose-response of residual γH2AX foci. The 
slope of the dose-response expressed high heterogeneity 
among the different patients (slope values range: 0.83-2.27). 
Using the slope of the foci dose-response as a parameter of 
tumour radiosensitivity we could determine 3 patients 
subgroups, namely resistant, with slope values lower than the 
25th percentile of the slope values distribution (<1.1); 
moderate, with slope values between the 25 and 75th 
percentile and sensitive, with slope values above the 75th 
percentile (>1.8). These results are consistent with previously 
observed slope values for very sensitive (e.g. seminoma, 
slope value >2) and resistant (e.g. GBM, slope value ~1) 
tumour types. ANOVA analysis of the residual foci values post 
4 Gy IR evaluated in tumour cells form different parts of the 
same tumour revealed no significant differences in the foci 
value distributions. 
 
Conclusion: We herein show for the first time that the γH2AX 
ex vivo assay is clinically feasible and able to detect 
differences in cellular radiation sensitivity among patients 
with the same tumour type. Our results suggest that 
intratumoural heterogeneity (potential source of sampling 
error) do not significantly affect the results of the assay. 
Taken together, this assay has a promising potential for 
individualized radiation oncology and prospective validation 
in different tumour types in relation to known tumour 
characteristics and patient’s outcome is warranted. 
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Purpose or Objective: The aim of the project is to present 
an in vitro 3D cellular platform capable of measuring 
radiation-induced cell damage at the cellular scale, enabling 
high-resolution image capture of cell response along the 
proton depth dose.  
 
Material and Methods: A 3D cancer model of dimensions 17 
mm x 17 mm x 5 mm (L x W x H) was developed for proton 
irradiation. The model comprises 1 million uniform 
distributed HT29 colon cancer cells within a type 1 collagen 
scaffold. The model was irradiated with 62 MeV proton 
spread out Bragg peak (SOBP) of 10 mm width. Samples were 
fixed after irradiation, set within agarose gel, processed via 
vibratome to 400 nm thickness slices, stained with markers 
for apoptosis (Caspase-3), DNA double strand breaks (53BP1) 
and hypoxia (CA9). 
 
Results: Alamar blue assay proves the cell metabolism can 
maintain 1-5 days depending on seeding density. The cancer 
cells invade into stroma, form spheroid and show paracrine 
activity (vascular endothelial growth factor and epidermal 
growth factor receptor expression) and hypoxia gradients in 
3D model. The measurement of DNA double strand breaks is 
achievable in 2D fluorescent microscopy but less easily 
resolvable in 3D imaging. The level of cell apoptosis along 
SOBP can be imaged and correlated to the actual position and 
dose. Figure below shows 1 million HT29 3D models are 
irradiated by 5Gy dose and fixed 24 hour after irradiation. 
The image position located at the proximal edge of the SOBP. 
 
 
 
Conclusion: In this novel methodology of sample processing 
and well-controlled coordination system, correlation between 
the cell response of the 3D cancer model and proton dose 
distribution was possible. The fluorescent images show a 
clear difference in cell apoptosis signal response with depth 
dose, and in the 3D samples we could image a hypoxia 
gradient. Further work is underway to model LET within the 
3D cancer model to be linked to cell response parameters, 
and to repeat the experiment under x-ray irradiation. 
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Purpose or Objective: Late radiation enteropathy affects 
20% of prostate cancer survivors. Inflammatory processes may 
relate to its occurrence. We aimed to assess differences in 
the levels of intestinal mucosa cytokines between patients 
with side-effects after pelvic radiotherapy and healthy 
controls. 
 
Material and Methods: Patients with GI symptoms developing 
after prostate radiotherapy and undergoing colonoscopy were 
recruited for this study. Controls were patients undergoing 
colonoscopy for polyp surveillance. All participants were free 
of bowel cancer. Colonoscopy was performed after standard 
preparation of the bowel with citramag and senna or Kleen 
prep. Biopsies were obtained for cytokine characterization 
and pathologic assessment as follows (Fig.1): 
- (1) Two endoscopic directed biopsies were taken from an 
area where mucosal radiation lesion was present; if no 
mucosal change was obvious, biopsies were taken from the 
anterior rectal wall.  
- (2) A second pair of biopsies was taken from normal looking 
mucosa as close as possible to the previous sampling site. 
